Date: 2011-04-29
Type of information: Initiation of preclinical development
phase: 2
Announcement: initiation
Company: Siena Biotech (Italy)
Product: SEN0014196 (6-chloro-2,33,4,9-tetrahyddro-1H-carbaazole-1-carbooxamide)
Action
mechanism: SEN0014196 is a Sirt1 inhibitor.Sirt1 is a member of the family of sirtuin proteins. The name sirtuin comes from the Silent Information Regulator gene 2 (Sir2), a gene which is associated with aging in yeast and invertebrates. The equivalent gene in mammals is called Sirt1.
Disease: Huntington's Disease
Therapeutic area: Genetic diseases - Neurodegenerative diseases - Rare diseases
Country: Europe
Trial details:
Latest
news: Siena Biotech has announced that SEN0014196 has entered Phasse II trials in Huntington's disease patients. The compound is being developed as a disease-modifying therapy in Huntington's disease and has previously obtained Orphan Drug status both from the FDA and the EMA. Siena Biotech also announced that an upcoming Phase II study has been endorsed by the European Huntington's Disease Network (EHDN), a non-profit organization of HD clinicians, researchers and HD families (wwww.euro-hd.net). It will be conducted at multiple study sites of the network in Germany, Great Britain and Italy, ensuring rapid recruitment and providing an experienced infrastructure for clinical research that has successfully completed several HD clinical trials in the past.
Following successful completion of a Phase I package in healthy volunteers during 2010, an exploratory study with SEN0014196 in patients with Huntington's disease (HD) has started across six European sites in a study which is co-funded by the European Commission under the Seventh Framework Programme. The study, with the acronym PADDINGTON aims to ascertain target engagement and provide pharmacodynamic data to guide subsequent efficacy studies.
